MedTrace Logo

Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)

NCT07435467 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2026-02-27

No results posted yet for this study

Summary

The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the retrospective analysis of Alzheimer's Disease and neurodegeneration biomarkers in an already available discovery cohort of 700 previously hospitalized geriatric patients.

Conditions

  • Alzheimer Disease
  • Old Age; Dementia

Interventions

OTHER

collection of blood samples

Serum and EDTA-plasma samples will be collected at baseline

Sponsors & Collaborators

  • Ministry of Health, Italy

    collaborator OTHER_GOV

  • University of Salento

    collaborator OTHER

  • IRCCS Multimedica

    collaborator OTHER

  • Azienda Ospedaliera Universitaria Policlinico "G. Martino"

    collaborator OTHER

  • Istituto Nazionale di Ricovero e Cura per Anziani

    lead OTHER

Principal Investigators

  • Fabiola Olivieri, Professor · IRCCS INRCA, Ancona, Italy

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-09
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07435467 on ClinicalTrials.gov